

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**POLL RESULTS OF
THE 2026 SECOND EXTRAORDINARY GENERAL MEETING**

Reference is made to the circular (the “**Circular**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) dated August 14, 2026 incorporating, amongst others, the notice (the “**Notice**”) of the 2026 second extraordinary general meeting (the “**2026 Second EGM**”) of the Company. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE 2026 SECOND EGM

The Board is pleased to announce that the 2026 Second EGM was convened at 10:00 a.m. on Thursday, September 3, 2026, at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC.

The 2026 Second EGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and chaired by Mr. Wang Guohui, an executive Director and Chairman of the Board. All directors of the Company, namely Mr. Wang Guohui, Ms. Zhang Kun, Mr. Wei Jiawei, Mr. Chen Shaoxiong, Mr. Chen Gang, Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping, attended the 2026 Second EGM either in person or by electronic means.

The total number of issued Shares as at the date of the 2026 Second EGM was 39,834,408 Shares, comprising 31,565,804 H Shares and 8,268,604 Unlisted Shares. Pursuant to Rule 17.05A of the Listing Rules, the trustee of the 2021 H Share Incentive Scheme adopted by the Company abstained from voting at the 2026 Second EGM in respect of the unvested incentive Shares (i.e. 255,000 H Shares) held by it. In addition, as of the date of the 2026 Second EGM, 972,400 H Shares were treasury shares (“**Treasury Shares**”) held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited and no voting rights of the Treasury Shares were exercised at the 2026 Second EGM. As a result, the total number of eligible Shares that entitled the Shareholders to attend and vote on the resolutions proposed at the 2026 Second EGM was 38,607,008 Shares.

Shareholders (including proxies) representing 15,343,276 Shares (including 7,980,892 H Shares and 7,362,384 Unlisted Shares) or approximately 39.48% of the total issued shares (excluding Treasury Shares) of the Company attended the 2026 Second EGM.

As of the date of the 2026 Second EGM, save for the Treasury Shares, there were no repurchased Shares and therefore no Shares are pending cancellation and should be excluded from the total number of issued Shares entitled to attend and vote on all the resolutions at the 2026 Second EGM.

To the best knowledge, information and belief of the Company: save as disclosed above, (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the 2026 Second EGM as set out in Rule 13.40 of the Listing Rules; (2) other than the trustee of the 2021 H Share Incentive Scheme adopted by the Company who abstained from voting at the 2026 Second EGM in respect of the unvested incentive Shares (i.e. 255,000 H Shares) held by it, no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the 2026 Second EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the 2026 Second EGM.

POLL RESULTS OF THE 2026 SECOND EGM

The poll results of the resolutions proposed at the 2026 Second EGM are as follows:

Special Resolutions		Number of votes and percentage of the total voting Shares at the 2026 Second EGM			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the proposed issue of A Shares as follows (each and every items as a separate resolution):				
	i. Class of new Shares to be issued: Ordinary Shares (A Shares)	15,343,276 100.00%	0 0%	0 0%	Yes
	ii. Place of listing	15,343,276 100.00%	0 0%	0 0%	Yes
	iii. Nominal value of new Shares to be issued	15,343,276 100.00%	0 0%	0 0%	Yes
	iv. Issue size	15,343,276 100.00%	0 0%	0 0%	Yes
	v. Target subscribers	15,343,276 100.00%	0 0%	0 0%	Yes
	vi. Method of issuance	15,343,276 100.00%	0 0%	0 0%	Yes
	vii. Method of underwriting	15,343,276 100.00%	0 0%	0 0%	Yes
	viii. Pricing methodology and issue price	15,343,276 100.00%	0 0%	0 0%	Yes
	ix. Schedule of issuance	15,343,276 100.00%	0 0%	0 0%	Yes
	x. Use of the proceeds	15,343,276 100.00%	0 0%	0 0%	Yes
	xi. Validity period of the resolutions	15,343,276 100.00%	0 0%	0 0%	Yes
2.	To consider and approve the authorization to the board of directors to fully handle matters in connection with the issue of A Shares and the listing on the Sci-Tech Board.	15,343,276 100.00%	0 0%	0 0%	Yes

Special Resolutions		Number of votes and percentage of the total voting Shares at the 2026 Second EGM			Passed by Shareholders
		For	Against	Abstain	
3.	To consider and approve the use of proceeds raised from the issue of A Shares and the listing on the Sci-Tech Board.	15,343,276 100.00%	0 0%	0 0%	Yes
4.	To consider and approve the proposal for accumulated profit distribution and the plan for undertaking unrecovered losses prior to the issue of A Shares and the listing on the Sci-Tech Board.	15,343,276 100.00%	0 0%	0 0%	Yes
5.	To consider and approve the analysis on dilution on immediate return by the Company's initial public offering of A shares and adoption of recovery measures for the immediate return.	15,343,276 100.00%	0 0%	0 0%	Yes
6.	To consider and approve the Company's Three-Year Dividend Distribution Plan for Shareholders after the Initial Public Offering of A Shares and the Listing on the Sci-Tech Board and profit distribution policy.	15,343,276 100.00%	0 0%	0 0%	Yes
7.	To consider and approve the Company's Share Price Stabilization Plan for the Three Years after the Initial Public Offering of A Shares and the Listing on the Sci-Tech Board.	15,343,276 100.00%	0 0%	0 0%	Yes
8.	To consider and approve the undertakings and restraining measures relating to the issue of A Shares and listing on the Sci-Tech Board, and to authorize the board of directors to make appropriate undertakings for the purpose of the issue of A Shares in accordance with the laws, regulations and regulatory documents of the PRC, the relevant regulations and policies of the securities regulatory departments, and combining the review for listing on the Sci-Tech Board in practice and the actual situation of the Company.	15,343,276 100.00%	0 0%	0 0%	Yes

Special Resolutions		Number of votes and percentage of the total voting Shares at the 2026 Second EGM			Passed by Shareholders
		For	Against	Abstain	
9.	To consider and approve the status of major transactions with related parties during the track record period (i.e. the three years ended December 31, 2023, 2024 and 2025 and the six months ended June 30, 2026).	712,225 100.00%	0 0%	0 0%	Yes
10.	To consider and approve the proposed amendments to the articles of association of the Company.	15,273,351 99.54%	69,925 0.46%	0 0%	Yes
Ordinary Resolutions					
11.	To consider and approve the amendment to the “Rules of Procedures for Shareholders’ General Meetings”.	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
12.	To consider and approve the amendment to the “Rules of Procedures for the Board of Directors”.	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
13.	To consider and approve the amendments to or adoption of each of the following internal management policies (each and every items as an ordinary resolution):				
i.	the “Decision-Making Policies for Related (Connected) Transactions”	15,343,276 100.00%	0 0%	0 0%	Yes
ii.	the “Terms of Reference for the Independent Non-executive Directors”	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
iii.	the “Management Policies for External Guarantees”	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
iv.	the “Management Measures for External Investments”	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
v.	the “Management Policies for Raised Proceeds”	15,279,626 99.59%	63,650 0.41%	0 0%	Yes
vi.	the “Implementation Rules for Online Voting”	15,343,276 100.00%	0 0%	0 0%	Yes

Ordinary Resolutions		Number of votes and percentage of the total voting Shares at the 2026 Second EGM			Passed by Shareholders
		For	Against	Abstain	
14.	To consider and approve the proposed amendments to the 2025 H Share Incentive Scheme adopted by the Company at the extraordinary general meeting of the Company dated May 26, 2025.	15,279,626 99.59%	63,650 0.41%	0 0%	Yes

As more than two-thirds of the votes were cast in favour of the Special Resolutions numbered 1 to 10 above, and more than half of the votes were cast in favour of the Ordinary Resolutions numbered 11 to 14 above, all resolutions proposed at the 2026 Second EGM were duly passed by way of poll by the Shareholders.

SCRUTINEERS

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the 2026 Second EGM for the purpose of vote-taking.

Further announcement will be made by the Company in connection with the matters resolved at the 2026 Second EGM as and when appropriate.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, September 3, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.